13. 多発性硬化症/視神経脊髄炎
[臨床試験数:3,050,薬物数:2,147(DrugBank:348),標的遺伝子数:244,標的パスウェイ数:228

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01647880
(ClinicalTrials.gov)
July 201323/7/2012MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)Phase II/III Study to Investigate the Effects of Fingolimod Versus Interferon Beta-1b on Visual Recovery After Optic NeuritisMultiple SclerosisDrug: Verum arm receiving Gilenya®;Drug: Active Comparator receiving Extavia®Charite University, Berlin, GermanyNeuroCure Clinical Research Center, Charite, BerlinTerminated18 Years55 YearsAll15Phase 2;Phase 3Germany
2EUCTR2011-004787-30-DE
(EUCTR)
26/10/201213/07/2012Modification of the visual outcome after optic neuritis in CIS or MS by Gilenya®Modification of the visual outcome after optic neuritis in CIS or MS by Gilenya® - MOVING Multiple sclerosis or clinically isolated syndrom;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Gilenya®
Product Name: Gilenya®
Product Code: Gilenya®
INN or Proposed INN: Fingolimod
Other descriptive name: FINGOLIMOD
Trade Name: Extavia®
Product Name: Extavia®
Product Code: Extavia®
INN or Proposed INN: Interferon beta 1B
Other descriptive name: INTERFERON BETA-1B
Charite Universitaetsmedizin BerlinNULLNot RecruitingFemale: yes
Male: yes
Phase 3Germany
3EUCTR2011-001956-12-CZ
(EUCTR)
25/05/201104/05/2011Biological Efficacy of Interferon ß Therapy in Patients with Multiple SclerosisMonitoring of MxA mRNA Expression as a Marker of Rresponse to Interferon ß Therapy in Patients with Multiple Sclerosis. To correlate bioactivity of IFNß reflected by level of MxA expression and clinical course of MS To measure expression of MxA protein in patients treated with IFNß depending on NAbs statusNAbs positive cohorts will be correlated NAbs titer with level of MxA expression, respectively if the MxA decrease is not preceding NAbs positivity. The MxA induction test will be tested.Trade Name: Avonex®
Product Name: Avonex®
Product Code: EU/1/97/033/002
Trade Name: Betaferon®
Product Name: Betaferon®
Product Code: EU/1/95/003/005-010
Trade Name: Rebif 22®
Product Name: Rebif 22®
Product Code: EU/1/98/063/001-003
Trade Name: Rebif 44®
Product Name: Rebif 44®
Product Code: EU/1/98/063/004-006
Trade Name: Extavia®
Product Name: Extavia®
Product Code: EU/1/08/454/001-002, EU/1/08/454/005-007
University Hospital MotolNULLNot RecruitingFemale: yes
Male: yes
Phase 4Czech Republic